Resolution of persistent SARS-CoV-2 infection with prolonged intravenous remdesivir and vaccination in a patient post CAR-T

Ambati, Sai, Ali, Bazga, Seddon, Owen, Godkin, Andrew ORCID: https://orcid.org/0000-0002-1910-7567, Scurr, Martin ORCID: https://orcid.org/0000-0002-4120-0688, Moore, Catherine, Rowntree, Clare and Underwood, Jonathan ORCID: https://orcid.org/0000-0001-6963-2821 2023. Resolution of persistent SARS-CoV-2 infection with prolonged intravenous remdesivir and vaccination in a patient post CAR-T. International Journal of Hematology 10.1007/s12185-022-03518-2

Preview

PDF - Published Version Available under License Creative Commons Attribution. Download (795kB) | Preview

Abstract

SARS-CoV-2 virus is a single-stranded enveloped RNA virus, which causes coronavirus disease. Most of the immunocompetent patients with SARS-CoV-2 infection do have mild to moderate respiratory illness; however, in immunocompromised patients, the course of infection is unpredictable with high rates of infectivity and mortality. So, it is important to identify the immunocompromised patients early and establish the course of treatment accordingly. Here, we describe a 25-year-old male with background of B cell ALL, post-BMT and CAR-T therapy who received treatment with remdesivir and vaccination and was followed up for six months from the onset of symptoms to post vaccination, which showed resolution of symptoms and improvement of immunological markers. Here, we review the literature concerning the course and treatment of SARS-CoV-2 infection aimed at achieving cure in this patient.

Item Type:	Article
Date Type:	Published Online
Status:	Published
Schools:	Medicine
Publisher:	Springer
ISSN:	0925-5710
Date of First Compliant Deposit:	23 March 2023
Date of Acceptance:	14 December 2022
Last Modified:	08 May 2023 19:40
URI:	https://orca.cardiff.ac.uk/id/eprint/157901

Actions (repository staff only)

Edit Item